Tuesday 21st April

Welcome Reception / Registration / Poster set up

Wednesday 22nd April

Session: PBPK: past, present and future
Session Chair: Ioannis Konstantinidis & Stephan Schaller

Welcome to the First International PBPK Conference & session intro
Ioannis Konstantinidis, Novartis

Local Host Introduction

Aligning PBPK, Patients and R&D to Create a Common Future
Thierry Lave, Independent Consultant

PBPK: Did a Knock Down in Round 1; What to Expect for Round 2?
Amin Rostami, University of Manchester

PBPK/QSP models
Lars Kuepfer, Aachen University

Session: DDI
Session Chair: Youssef Daali & Kenichi Umehara

Unravelling DDIs in absence of *in vitro* signals
Pradeep Sharma, AZ

DDI with intestinal Pgp inhibition and Induction
Aki Heikkinen, Certara

Transitioning from Transcriptomics to Proteomics
Chen Ning, KU Leuven

Rapid Fire Oral Presentations 5 mins each.

Session: Regulatory "debate" session
Session Chair: Kunal Taskar & Loeckie De Zwart

Andrew Butler, MHRA
Pieter Colin, EMA
Yuching Yang, FDA

Open discussion/ Debate

Thursday 23rd April

Introducing PBPK Nexus, our plans, our future.
Chara Litou, Certara

Session: Special Populations
Session Chair: Loeckie De Zwart & Pieter Annaert

PBPK Modeling to support dosing and Risk Assessment in Pregnancy and Lactation
Sophie Fischer, ESQLabs

Lactation PBPK: Impact of CYP2D6 phenotype on Fluoxetine
Amita Pansari, Certara

Predicting Cefixime exposure during pregnancy using PBPK
Simon Koele, Radboud University

PBPK modeling of the impact of Organ impairment on PK
Agustos Ozbey, Idorsia

PBPK modeling of Elexacaftor, Tezacaftor, and Ivacaftor to predict clinical DDI and impact on moderate Hepatic Impairment Population
Jiangfan Wu, University Munich

PBPK modelling to investigate the impact of hepatic impairment on the pharmacokinetics of biologics
Felix Stader, Certara

Session: Biomarkers / Disease
Session Chair: Maxime Le Merdy & Abla Nada Geiser

Bilirubin metabolism in health and disease and its comparison with RWD
Ahenk Zeynep Sayin, University Hospital Aachen

GI Tissue exposures Crohn's Disease
Simon Teague, Pharmaron

LAI in Obesity
Mattia Berton, Roche

Rapid Fire Oral Presentations 5 mins each.

Session: Biologics
Session Chair: Neil Parrott & Pradeep Sharma

Application of PBPK for long-acting peptide therapeutics
Howard Burt, Novo Nordisk

PBPK of tumor targeting bispecific mAbs
Armin Sepp, Certara

PBPK of Subcutaneous Absorption for mAbs
Erik Sjoegren, Uppsala

Friday 24th April

Session: Innovative Approaches
Session Chair: Chara Litou & Bhagwat Prasad

New Approach Methodologies and PBPK integration
Bhagwat Prasad, Cincinnati Children's Hospital

A review of virtual twins in PBPK
Emily Mannix, Monash University

State-of-the-Art Cluster Gauss-Newton method redefines what PBPK models can address in early clinical development
Toshiaki Tsuchitani, Keio University

Comparative Evaluation of Standard PBPK, High-Throughput PBPK and Structure-Based Machine Learning for FIH predictions
Silvan Kaeser, Roche

Liquid Biopsy–Informed Physiologically Based Pharmacokinetic Modeling of Systemic Exposure to Tyrosine Kinase Inhibitors in Leukemia
Amit Dahal, Rhode Island

Session: Oral Absorption
Session Chair: André Dallmann & Nikoletta Fotaki

Food effect prediction of a BCS class II drug formulated as an ASD
Paul Vrenken, Pharmetheus

PBBM of Regional and Colon Absorption in Humans
Harshad Jadhav, AZ

Establishing a PBBM framework to investigate the absorption process of poorly soluble drugs administered as ASDs
Julia Macente, J&J

From Dissolution to PBPK: A Probabilistic, Literature-Driven Framework for Risk-Informed Bioequivalence Evaluation
Jhennifer Rabelo, Universidade de São Paulo

PBPK CONFERENCE BASEL 2026